Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions

Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions Curr Pathobiol Rep (2017) 5:243–252 DOI 10.1007/s40139-017-0147-5 PATHOBIOLOGY OF ORPHAN DISEASES (S RANGANATHAN, SECTION EDITOR) Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions 1,2 1,2,3,4,5 Ellen L. Mitchell & Zahida Khan Published online: 10 July 2017 Springer Science+Business Media, LLC 2017 Abstract serum protein also predisposes patients to pan lobar emphy- Purpose of Review The aim of the study is to review the liver sema as adults. At this time, the only approved therapy for disease caused by alpha-1 antitrypsin deficiency (A1ATD), A1ATD-associated liver disease is orthotopic liver transplan- including pathogenesis, epidemiology, diagnostic testing, tation, which is curative. However, there has been significant and recent therapeutic developments. recent progress in the development of small molecule thera- Recent Findings Therapeutic approaches target several intra- pies with potential both to preserve the native liver and pre- cellular pathways to reduce the cytotoxic effects of the vent hepatotoxicity. misfolded mutant globular protein (ATZ) on the hepatocyte. These include promoting ATZ transport out of the endoplas- . . . Keywords PiZ mouse Autophagy ATZ Liver . . mic reticulum (ER), enhancing ATZ degradation, and transplantation SERPINA1 Bile acid preventing ATZ globule-aggregation. Summary A1ATD is the leading genetic cause of liver http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Pathobiology Reports Springer Journals

Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions

Loading next page...
 
/lp/springer_journal/liver-disease-in-alpha-1-antitrypsin-deficiency-current-approaches-and-5b10vkzWcq
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Pathology
eISSN
2167-485X
D.O.I.
10.1007/s40139-017-0147-5
Publisher site
See Article on Publisher Site

Abstract

Curr Pathobiol Rep (2017) 5:243–252 DOI 10.1007/s40139-017-0147-5 PATHOBIOLOGY OF ORPHAN DISEASES (S RANGANATHAN, SECTION EDITOR) Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions 1,2 1,2,3,4,5 Ellen L. Mitchell & Zahida Khan Published online: 10 July 2017 Springer Science+Business Media, LLC 2017 Abstract serum protein also predisposes patients to pan lobar emphy- Purpose of Review The aim of the study is to review the liver sema as adults. At this time, the only approved therapy for disease caused by alpha-1 antitrypsin deficiency (A1ATD), A1ATD-associated liver disease is orthotopic liver transplan- including pathogenesis, epidemiology, diagnostic testing, tation, which is curative. However, there has been significant and recent therapeutic developments. recent progress in the development of small molecule thera- Recent Findings Therapeutic approaches target several intra- pies with potential both to preserve the native liver and pre- cellular pathways to reduce the cytotoxic effects of the vent hepatotoxicity. misfolded mutant globular protein (ATZ) on the hepatocyte. These include promoting ATZ transport out of the endoplas- . . . Keywords PiZ mouse Autophagy ATZ Liver . . mic reticulum (ER), enhancing ATZ degradation, and transplantation SERPINA1 Bile acid preventing ATZ globule-aggregation. Summary A1ATD is the leading genetic cause of liver

Journal

Current Pathobiology ReportsSpringer Journals

Published: Jul 10, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off